Literature DB >> 12823595

Predicting progression to cirrhosis in chronic hepatitis C virus infection.

A J Freeman1, M G Law, J M Kaldor, G J Dore.   

Abstract

A systematic evaluation of published studies was undertaken to identify factors associated with accelerated fibrosis progression in patients with chronic hepatitis C virus (HCV) infection. An ecologic analysis was used to estimate relative risk (RR) of cirrhosis across four study methodologies: liver clinic series, post-transfusion cohorts, community-based studies and blood donor series. In each study category, the following factors were independently associated with disease progression: male sex (RR = 1.08); heavy alcohol consumption (RR = 1.61); elevated serum ALT levels (RR = 1.23) and histology demonstrating high-grade necro-inflammatory activity. After adjusting for these cofactors, older age at HCV infection and acquisition of HCV through blood transfusion were not implicated in influencing disease outcome. Although not able to be examined in this study,co-infection with HIV, and to a lesser extent HBV, is also likely to result in worse outcomes for patients with chronic HCV infection. Virological factors such as HCV genotype, viral load and quasispecies diversity are less likely to be important. A Weibull distribution was used to model disease progression at a population level. The influence of cofactors on individual prognosis was examined and an algorithm to predict the risk of subsequently developing cirrhosis is presented.

Entities:  

Mesh:

Year:  2003        PMID: 12823595     DOI: 10.1046/j.1365-2893.2003.00436.x

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  15 in total

1.  Prognostic factors associated with hepatitis C disease: a case-control study utilizing U.S. multiple-cause-of-death data.

Authors:  Matthew Wise; Lyn Finelli; Frank Sorvillo
Journal:  Public Health Rep       Date:  2010 May-Jun       Impact factor: 2.792

2.  Cost-effectiveness and population outcomes of general population screening for hepatitis C.

Authors:  Phillip O Coffin; John D Scott; Matthew R Golden; Sean D Sullivan
Journal:  Clin Infect Dis       Date:  2012-03-12       Impact factor: 9.079

3.  Disadvantages of peginterferon and ribavirin treatment in older patients with chronic hepatitis C: an analysis using the propensity score.

Authors:  Hirotoshi Ebinuma; Hidetsugu Saito; Shinichiro Tada; Nobuhiro Nakamoto; Tazuko Ohishi; Satoshi Tsunematsu; Naoki Kumagai; Kanji Tsuchimoto; Nobuhiro Tsukada; Yasutaka Inagaki; Yoshinori Horie; Masahiko Takahashi; Kazuhiro Atsukawa; Yukishige Okamura; Takanori Kanai; Toshifumi Hibi
Journal:  Hepatol Int       Date:  2011-09-10       Impact factor: 6.047

4.  Factors influencing the rate of fibrosis progression in chronic hepatitis C.

Authors:  Conrado M Fernández-Rodriguez; Maria Luisa Gutiérrez; Pilar López Serrano; José L Lledó; Cecilio Santander; Teresa Pérez Fernández; Esperanza Tomás; Guillermo Cacho; Manuel Nevado; Maria Luisa Casas
Journal:  Dig Dis Sci       Date:  2004 Nov-Dec       Impact factor: 3.199

5.  Fibrosis progression in paired liver biopsies from HIV/HCV co-infected patients.

Authors:  Monica Schiavini; Elena Angeli; Annalisa Mainini; Caterina Uberti-Foppa; Pietro Zerbi; Caterina Sagnelli; Antonietta Cargnel; Gianluca Vago; Pier Giorgio Duca; Riccardo Giorgi; Giuliano Rizzardini; Guido Gubertini
Journal:  Hepat Mon       Date:  2011-07-01       Impact factor: 0.660

Review 6.  Assessment of cost of innovation versus the value of health gains associated with treatment of chronic hepatitis C in the United States: The quality-adjusted cost of care.

Authors:  Zobair M Younossi; Haesuk Park; Douglas Dieterich; Sammy Saab; Aijaz Ahmed; Stuart C Gordon
Journal:  Medicine (Baltimore)       Date:  2016-10       Impact factor: 1.889

7.  Chronic Hepatitis C-Related Cirrhosis Hospitalization Cost Analysis in Bulgaria.

Authors:  Maria Dimitrova; Kaloyan Pavlov; Konstantin Mitov; Jordan Genov; Guenka Ivanova Petrova
Journal:  Front Med (Lausanne)       Date:  2017-08-07

8.  A record-linkage study of the development of hepatocellular carcinoma in persons with hepatitis C infection in Scotland.

Authors:  S A McDonald; S J Hutchinson; S M Bird; C Robertson; P R Mills; J F Dillon; D J Goldberg
Journal:  Br J Cancer       Date:  2008-09-02       Impact factor: 7.640

9.  Impact of Wisteria floribunda Agglutinin-Positive Mac-2-Binding Protein in Patients with Hepatitis C Virus-Related Compensated Liver Cirrhosis.

Authors:  Kunihiro Hasegawa; Ryo Takata; Hiroki Nishikawa; Hirayuki Enomoto; Akio Ishii; Yoshinori Iwata; Yuho Miyamoto; Noriko Ishii; Yukihisa Yuri; Chikage Nakano; Takashi Nishimura; Kazunori Yoh; Nobuhiro Aizawa; Yoshiyuki Sakai; Naoto Ikeda; Tomoyuki Takashima; Hiroko Iijima; Shuhei Nishiguchi
Journal:  Int J Mol Sci       Date:  2016-09-12       Impact factor: 5.923

10.  Comparison of liver biopsies before and after direct-acting antiviral therapy for hepatitis C and correlation with clinical outcome.

Authors:  Omar A Saldarriaga; Bradley Dye; Judy Pham; Timothy G Wanninger; Daniel Millian; Michael Kueht; Benjamin Freiberg; Netanya Utay; Heather L Stevenson
Journal:  Sci Rep       Date:  2021-07-15       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.